Clinical and Diagnostic Laboratory Immunology, July 1998, p. 556-560, Vol. 5, No. 4
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Department of Medicine, University Hospitals and CWRU School of Medicine, Cleveland, Ohio1; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland2; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts3; Department of Pediatrics, University of Colorado Health Sciences Center, Denver, Colorado4; and Center for Interdisciplinary Research in Immunology and Disease, University of California, Los Angeles, California5
Received 19 December 1997/Returned for modification 2 March 1998/Accepted 13 May 1998
| |
ABSTRACT |
|---|
|
|
|---|
Measures of immune function have become increasingly important as
endpoints in AIDS clinical trials, with respect to both modulation and
reconstitution of immunity by experimental therapies. Measurement
of immune function in this setting requires the development of
robust analytic approaches suitable for the clinical laboratory. Experiments were performed to evaluate the suitability of using cultured heparinized ("whole") blood for induction of tumor
necrosis factor alpha (TNF-
) and gamma interferon (IFN-
), two
cytokines critical in AIDS pathogenesis. TNF-
expression ranged from
229 to 769 pg/ml in lipopolysaccharide (LPS)-stimulated cultures and was not detected in unstimulated cultures. IFN-
expression ranged from 0 to 112,000 pg/ml in phytohemagglutinin A (PHA)-stimulated cultures and from 0 to 789 pg/ml in antigen-stimulated cultures. The
mean coefficient of variation observed in three weekly determinations was 0.47 for TNF-
and ranged from 0.12 to 1.73 for IFN-
. These values indicate that sample sizes of 8, 24, and 29 subjects would be
sufficient to detect twofold changes in LPS-induced TNF-
and in PHA-
and antigen-induced IFN-
, respectively, if two baseline and two
treatment determinations were obtained, and if the interpatient variability of changes in true levels from baseline to follow-up is
negligible compared to the variability in the three weekly measurements. Measurement of LPS-induced TNF-
and mitogen- or antigen-induced IFN-
can be performed simply and reproducibly in
human immunodeficiency virus-infected persons by the whole-blood culture method. Further studies are warranted to determine the effect
of overnight shipping on assay reproducibility and to determine the
extent to which responses can be reliably detected in subjects with low
CD4 cell numbers.
| |
INTRODUCTION |
|---|
|
|
|---|
An increasing body of evidence suggests that highly active antiretroviral therapy (HAART) can effectively control human immunodeficiency virus (HIV) replication, increase CD4 cell numbers, and prolong survival for AIDS patients. Much less is known regarding the extent to which normal immune function is restored by such therapy. Although one prospective study (AIDS Clinical Trials Group [ACTG] study 315) reported partial immune reconstitution in subjects responding to HAART (15), several cases of disseminated Mycobacterium avium or cytomegalovirus infection have been reported in patients with unusually high CD4 cell counts in the setting of HAART (13, 21), raising the possibility that restoration of CD4 cell numbers may not necessarily lead to improved host defenses against AIDS-associated pathogens.
Measurement of immune function in the setting of a multicenter study
requires standardized, robust methods appropriate for a clinical-trials
laboratory. In 1996, the Advanced Technology Laboratory (ATL) program
of the ACTG was created and charged with the development and validation
of such methods. The objectives of the ATL program included development
of a simple and reproducible method for measurement of antigen- and
mitogen-induced cytokine expression. Cytokine induction is usually
performed by using mononuclear cells isolated by density sedimentation.
The present study evaluated production of tumor necrosis
factor alpha (TNF-
) and gamma interferon (IFN-
) by using an
alternative approach which has been termed whole-blood culture. In this
method, diluted heparinized blood, rather than isolated mononuclear
cells, is placed into culture, and the cytokine content is analyzed
after an appropriate period of incubation. These two cytokines were
selected based on their role in HIV pathogenesis and immune induction.
The objectives of the pilot study were to determine optimal methods for
specimen handling and cell culture with respect to sensitivity,
reproducibility, and relationship to HIV disease stage.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Subjects. Subjects included persons with HIV type 1 (HIV-1) infection documented by Western blotting whose CD4 cell counts had been measured within the preceding 6 months, who did not have active opportunistic infections, whose antiretroviral therapy (if any) had not been altered during the preceding 3 months, and who were not receiving immunomodulating agents such as thalidomide, prednisone, or colony-stimulating factors. Healthy volunteers without known HIV-1 infection or risk factors were also recruited as controls. CD4 cell counts were not measured for this group but were assumed to be normal. CD4 cell counts were categorized as normal (>600/µl), moderately reduced (200 to 600/µl), or markedly reduced (<200/µl). Blood was collected into heparinized Vacutainer tubes. Cultures were initiated within 4 h of phlebotomy except as noted. Specimens were kept at room temperature between the times of phlebotomy and culture.
Cell culture.
Culture was performed by diluting either 200 or 100 µl of blood in medium (RPMI 1640 with 25 mM HEPES, endotoxin
tested, with added penicillin-streptomycin-L-glutamine
solution; Sigma) for a total volume of 1 ml. Cultures were performed in
24-well tissue culture plates (Corning). Cultures were performed either
unstimulated or with added phytohemagglutinin A (PHA) (5 µg/ml;
Sigma), Candida antigen (CASTA, 40 µg/ml; Greer Labs), or
Escherichia coli O26:b6 lipopolysaccharide (LPS) (10 or 100 ng/ml; Sigma). The antigen concentrations had previously been
determined as optimal in mononuclear cell culture. The range of LPS
concentrations was selected with the intent of providing suboptimal
stimulation, since LPS-induced TNF-
production in whole-blood or
monocyte culture reaches a maximum at concentrations of 1 to 10 µg/ml. Two noncommercial mycobacterial-antigen preparations were also
studied: purified protein derivative (PPD) of Mycobacterium
tuberculosis H37Rv and culture filtrate of Mycobacterium
avium LR114. These were propagated in Proskauer-Beck medium for 6 and 10 weeks, respectively. The M. tuberculosis culture was
autoclaved; the M. avium culture was not. Proteins of both
cultures were precipitated in 60% saturated ammonium sulfate,
dissolved in endotoxin-free water, and dialyzed against water. The
concentrations studied were 10 µg/ml (PPD) and 1 µg/ml (M. avium filtrate). Supernatants were collected after 20 h of
incubation at 37°C in a humidified 5% CO2 atmosphere for analysis of TNF-
; this duration of culture was selected to allow optimal cytokine expression by monocytes rather than T cells. Supernatants for analysis of IFN-
were collected after 72 h (3 days) for PHA-stimulated cultures and after 168 h (7 days) for antigen-stimulated cultures. Supernatants of unstimulated cultures were
collected after both 3 and 7 days as controls. All supernatants were
frozen at
70°C and were analyzed with a commercial enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions (Endogen). The catalog numbers and other ordering information for all reagents are described at
http://aactg.s-3.com/immmeth.htm.
Data analysis. Hypotheses were tested at the 0.05 level of significance without adjustment for multiple testing, except where indicated. To evaluate differences in results for different assay conditions, the result under each assay condition for each specimen was expressed as its deviation from the mean of all results under all assay conditions for that specimen. Differences in results and in coefficients of variation (CV) (over repeated measures on the same subject over time) among assays carried out under different conditions were tested with a Kruskal-Wallis rank sum test, or with pairwise comparisons using a Wilcoxon sign rank test with Bonferroni's correction for the number of comparisons. Correlations were tested with the Spearman rank correlation coefficient. Sample sizes were calculated so as to give 80% power to detect the specified change with a two-sided 0.05-level Wilcoxon sign rank test (based on the Wilcoxon test efficiency relative to the t test being at least 0.864 when the random variable may have a nonnormal distribution). For variance estimates, undetectable levels were assigned the value of 6.25 pg/ml (half the lower limit of detection). The CV was calculated as the ratio of the standard error to the mean.
| |
RESULTS |
|---|
|
|
|---|
TNF-
.
Eight subjects (three healthy, five infected with
HIV-1) were studied on 3 consecutive weeks at one site by the
whole-blood method. No TNF-
was detected in any of the unstimulated
cultures in which blood was diluted 10-fold in medium. One unstimulated culture diluted fivefold had low levels of TNF-
identified (22 pg/ml); the remainder had undetectable levels (<15 pg/ml).
. As shown in Table
1, the mean level of induced TNF-
was
459 pg/ml when blood was diluted 10-fold with medium and stimulated
with 100 ng of E. coli LPS/ml. Mean induced TNF-
levels
increased to 634 pg/ml when blood was diluted 5- rather than 10-fold
and decreased to 348 pg/ml when the LPS concentration was reduced to 10 ng/ml (P < 0.001). However, neither of these
modifications in culture conditions significantly affected the mean CV
observed over the 3-week interval. Mean TNF-
concentrations obtained
with 10 ng of LPS/ml correlated only partially with those obtained with
100 ng/ml (Spearman rank order correlation, 0.64; P = 0.095) when blood was diluted 10-fold; all other combinations
correlated moderately (P < 0.04).
|
. These reagents were selected because of the role of
mycobacteria as AIDS-related opportunistic pathogens and because
M. tuberculosis filtrate activates monocytes for cytokine
production through mechanisms which do not involve the LPS receptor or
LPS-binding protein (5, 9). Mean TNF-
concentrations in
M. avium filtrate- and M. tuberculosis
PPD-stimulated wells were 379 and 437 pg/ml, respectively; these did
not differ significantly from those of LPS-stimulated cultures (as
determined by pairwise tests of M. avium filtrate versus
each concentration of LPS, and of M. tuberculosis PPD versus each concentration of LPS, with Bonferroni's correction;
K = 4). There was a strong correlation between mean
LPS-induced TNF-
levels and mean levels of TNF-
induced by
M. avium (r = 0.81, P < 0.001), but not with mean levels of TNF-
induced by M. tuberculosis PPD (r = 0.23, P = 0.24). A weak correlation in responses to the two mycobacterial
reagents was identified (r = 0.46, P = 0.05).
Mean TNF-
production was strongly correlated with CD4 cell count
range in responses to E. coli LPS (r = 0.87, P = 0.02) and M. avium filtrate
(r = 0.82, P = 0.03), as shown in Table
2. A trend was identified for M. tuberculosis PPD (r = 0.7, P = 0.07). These relationships must be considered cautiously, however, due to the small sample size.
|
IFN-
.
The same subjects were studied for induction of
IFN-
. Spontaneous production of IFN-
occurred in 16 of 46 supernatants collected after 3 days. This occurred only in subjects
with normal CD4 cell numbers, was not affected by blood dilution, and
resulted in relatively low concentrations of IFN-
(mean
concentration in those with detectable cytokine, 132 pg/ml). In
PHA-stimulated cultures, IFN-
was detected in 36 of 46 cultures,
with a mean concentration (including all cultures) of 31,754 pg/ml. The
IFN-
concentration decreased when blood was diluted 5- rather than
10-fold (2,348 pg/ml; P = 0.025). The CV of IFN-
determinations at 10- and 5-fold dilutions did not differ. PHA-induced
concentrations of IFN-
at the two dilutions were very highly
correlated (r = 0.95, P < 0.0001).
responses to three antigen preparations
Candida
albicans, M. avium, and M. tuberculosis
were also evaluated. Mean concentrations are shown
in Table 3. There was no significant
relationship among responses to the three antigens. The CV for antigen
responses ranged from 0.15 to 1.73 and were not significantly greater
than that for PHA. Neither mean IFN-
concentrations nor CV differed when blood was diluted 5- rather than 10-fold.
|
production was correlated with CD4 cell count range for
cultures stimulated with PHA (r = 0.78, P < 0.05), M. tuberculosis PPD
(r = 0.85, P = 0.027), or M. avium filtrate (r = 0.87, P = 0.023), but not for C. albicans-stimulated cultures. Again,
these relationships must be considered cautiously because of the small sample size and the added potential variation due to differential exposure.
Sample size analysis.
The variability in these data was used
to calculate the required sample size for two representative studies in
which twofold changes from baseline measurements were to be analyzed.
In the case of TNF-
, this represents the extent of inhibition
following administration of pentoxifylline or thalidomide (4, 18,
26) and is less than the threefold change in lymphoproliferative
responses to some antigens identified in ACTG study 315. Estimates were developed for single and double determinations at 1-week intervals, at
both baseline and treatment time points. These estimates are based on
the assumption that the interpatient variability of change in true
level from baseline to follow-up is negligible compared to the combined
assay and biological variation in our three weekly measurements. The
results of this analysis are shown in Table 4. Fewer subjects were required for
evaluation of TNF-
, reflecting the greater stability of this
measurement over time. However, even for the most variable
measurement
antigen-induced IFN-
production
meaningful data would
likely be obtained from a study of as few as 30 subjects if two
determinations were made at each time point.
|
Effect of shipping.
To evaluate the potential performance of
the method in the setting of a multicenter clinical trial, replicate
specimens from two subjects from a second site were processed in three
ways. One heparinized Vacutainer from each subject was processed
normally. A second Vacutainer was opened in the clinic. One milliliter
of blood was removed and was added to a polypropylene tube containing 9 ml of medium. Both tubes were resealed, placed within a biohazard shipping container, and then shipped by Federal Express to the lab,
where they arrived the following morning. The results from this
experiment are shown in Table 5. The
values obtained for both TNF-
and IFN-
when undiluted blood was
shipped were highly correlated with those from blood processed
immediately (Spearman r = 0.79; P < 0.001). Those obtained when blood was diluted prior to being shipped
correlated less well (r = 0.48, P = 0.08).
|
| |
DISCUSSION |
|---|
|
|
|---|
The cytokines IFN-
and TNF-
are critical in host defenses
against a wide range of pathogens, in part through synergistic induction of macrophage production of nitric oxide for the killing of
intracellular pathogens (2, 3, 22). The capacity for production of IFN-
by CD4 cells, particularly in response to soluble
recall antigens, is progressively lost in HIV-1 infection (17,
24) and is thought to be a major factor in the pathogenesis of
AIDS-related opportunistic infections. The extent to which this
capacity is restored by HIV therapy and whether this restoration can be
used as a guide to clinical decisions regarding the cessation of
preventive therapy are important questions for AIDS research. In the
case of TNF-
, additional significance may arise from the role of
this cytokine in promoting HIV-1 expression by infected cells (14,
25). Thus, TNF-
inhibitors, such as pentoxifylline, thalidomide, and prednisone, may be useful adjuncts to standard antiretroviral therapy, particularly in those clinical circumstances where a strong stimulus for TNF-
expression may be present, as in
some opportunistic infections.
The standard method for cytokine induction involves isolation of
mononuclear cells by density sedimentation. This requires collection of
cells at the interface of two intermiscible liquids, after which the
cells must be washed, counted, and resuspended in medium with
added serum prior to culture. The method may not be well suited to a
busy laboratory. However, removal of erythrocytes, neutrophils, and
platelets appears not to be necessary in order to study
mononuclear-cell function. This is the basis for the whole-blood
culture, which was originally described for the study of lymphocyte
proliferation and has since been used to study the expression of
several cytokines in clinical and laboratory studies (1, 8, 12,
16, 20, 23, 26). The method is simple and robust and requires
only a small volume of blood. However, it is blood volume, rather than
the number of input cells, which is held constant in these cultures.
This may add an additional source of potential variation, both among
individuals and within individuals over time. Some researchers have
suggested that data from whole-blood cultures be reported on a
per-cell basis, adjusted according to the number of input
responding cells in the specimen (7). Such a calculation for
PHA-induced IFN-
production in this study yields values of 0 to 860 pg/103 CD4 cells in HIV-positive subjects and estimated
values of 470 to 1,030 pg/103 CD4 cells in control
subjects (based on an estimated CD4 cell count of 800/µl).
However, total cytokine production (rather than that on a
per-cell basis) may be more relevant in terms of assessment of clinical
immunity in a patient. Per-cell calculations may also not be
appropriate for situations in which the number of responding cells
cannot be determined (e.g., antigens) or in cases in which a cytokine
is produced by cells of multiple phenotypes.
The number of mononuclear cells in whole-blood cultures is only 10 to
20% of that in cultured isolated mononuclear cells. For this reason,
whole-blood cultures may be less sensitive in detecting IFN-
responses to antigens with low precursor cell frequencies, particularly
in individuals with low total numbers of lymphocytes. This suggests
that there may be a threshold below which no responses will be
detected. The small sample size of the current report limits any
conclusions as to the possible lower limit of CD4 cell numbers for
detection of antigen-stimulated responses, but this may be 100 to 250 cells/µl.
However, it may also be incorrect to assume that cytokine responses in
whole-blood culture are affected by blood dilution in a simple linear
relationship, particularly with respect to cultures in which
precursor frequencies do not approach limiting dilution. Doubling of
the cell density in this study resulted in increases in production of
only 38% for LPS-induced TNF-
and 22% for PHA-induced IFN-
.
Many immunoregulatory factors are present in blood, including
antibodies, other plasma factors, and products of other cell types.
Platelets, for example, are a potential source of transforming growth
factor
, a potent immunoregulating factor (10, 11).
Platelets are partially but inconsistently removed from mononuclear
cells during cell separation but are not removed in whole-blood
culture. Other factors may be removed during whole-blood culture by
adsorption onto erythrocyte membranes or interaction with antibody. In
all these cases, however, one may argue that the responses measured in
cultured whole blood may more accurately reflect those expressed in
vivo. Thus, conventional cell culture may be useful for defining the
function of isolated cells but may not reflect their interaction with
other host factors in a patient in vivo.
The variation observed in this study may have arisen from one or more
of three potential sources: biological variation, variation in cell
culture technique, and variation in analysis of cytokine content. The
high correlation of replicate wells in the cytokine ELISAs (which
generally differed by <5% [data not shown]) suggests that variation
in analysis of cytokine content is not a major factor. In other data
which were not presented, <5% variation was also observed in TNF-
responses in three specimens drawn in immediate succession in three
healthy individuals. These suggest that biological variation may
account for most of the variation that we observed. This may be
particularly true for CD4 cell responses, for which we found greater
variability than for TNF-
production (which mainly reflected
monocyte activation in the short-term cultures). The reported variation
in CD4 cell numbers may be as high as 0.19 within a 3-day interval
(6, 19). Most of this variation has been attributed to
variability in blood leukocyte counts, differential fractions of
lymphocytes, and total lymphocyte counts rather than in flow cytometry
per se. The variation in CD4 cell numbers over a 3-week interval has
not been studied, but these data suggest that much of the variation in
IFN-
production observed here may represent biological variation in
CD4 cell numbers.
The factors which may affect cytokine responses following shipping are
complex and include temperature, oxygen tension, pH, and nutrient
depletion. These factors are thought to be responsible for the reduced
lymphoproliferative responses in shipped specimens, particularly when
the specimens are held at 4°C (7). In addition, some
adherent cells (monocytes) may be lost to the surface of the tube
during this time. These factors were expected to result in reduced
expression of IFN-
and TNF-
in shipped blood and were the
rationale for the evaluation of shipped blood which had been diluted in
a polypropylene tube. Surprisingly, cytokine responses were generally
lower in specimens that had been shipped diluted rather than neat.
Further studies are required to determine the source of the variation
arising during shipping. Although the data presented suggest that
overnight shipping of undiluted blood does not interfere with the rank
order of results when stimulated and unstimulated specimens are
compared, the extent to which shipping will hinder quantitative
comparisons in clinical trials also requires further investigation.
Two approaches to measuring induced cytokines in the setting of a
multicenter trial, in which either blood or supernatants may be shipped
to a central location, may be considered. These two methods would each
introduce different types of variation. The effects of shipping may in
essence reflect the effects of time and temperature, which in turn may
depend on season, location, altitude of air transport, and
unpredictable factors such as traffic delays. To minimize these
effects, shipping containers should include additional mass (such
as an "ice pack" at room temperature) inside an insulated
vessel to provide maximum temperature stability. The alternative
approach, induction of cytokines on site, would necessitate a
training and certification process at each laboratory and might
restrict participation in a study. In the limited experience of the
Induced Cytokine Focus Group to date, laboratories which have not had
previous experience in long-term cell culture may experience unexpected
contamination and spurious results during initial attempts at cell
culture. For this reason, the certification process should include
documentation of low values of TNF-
in unstimulated cultures (since
this is the most sensitive indicator of contamination), as well as
documentation of adequate expression of IFN-
in PHA-stimulated
cultures. It may be appropriate for initial clinical trials to both
ship and perform cultures locally so that the variability introduced by
these methods may be directly compared.
In summary, measurement of LPS-induced TNF-
and mitogen- or
antigen-induced IFN-
can be performed simply by the whole-blood culture method. The method is sufficiently reproducible and stable over short intervals that relatively small sample sizes may be sufficient to find meaningful changes in clinical trials, although the
sensitivity may be a limiting factor in the analysis of IFN-
production in subjects with advanced disease. Additional studies are
necessary to determine whether cultures should be performed locally or
centrally (on shipped blood) in the context of multicenter studies and
to determine the relationship of HIV disease stage to cytokine
production.
| |
ACKNOWLEDGMENTS |
|---|
These studies were performed in the ACTG Immunology Advanced Technology Laboratories. This work was partially supported by NIH contracts 961C003 and 961C009.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: CWRU School of Medicine, 10900 Euclid Ave., Cleveland, OH 44106-4984. Phone: (216) 368-4844. Fax: (216) 368-2034. E-mail: rsw2{at}po.cwru.edu.
Focus group membership also includes R. P. Bucy, A. Craiu,
C. Dinarello, J. Fahey, M. Fletcher, Y. Mizrachi, J. Reuben, J. Siegel,
M. Wade, and S. Pahwa.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Bloemena, E., M. T. Roos, J. L. Van Heijst, J. M. Vossen, and P. T. Schellekens. 1989. Whole-blood lymphocyte cultures. J. Immunol. Methods 122:161-167[Medline]. |
| 2. |
Chan, J.,
Y. Tian,
K. E. Tanaka,
M. S. Tsang,
K. Yu,
P. Salgame,
D. Carroll,
Y. Kress,
R. Teitelbaum, and B. R. Bloom.
1996.
Effects of protein calorie malnutrition on tuberculosis in mice.
Proc. Natl. Acad. Sci. USA
93:14857-14861 |
| 3. | Deckert Schluter, M., A. Rang, D. Weiner, S. Huang, O. D. Wiestler, H. Hof, and D. Schluter. 1996. Interferon-gamma receptor-deficiency renders mice highly susceptible to toxoplasmosis by decreased macrophage activation. Lab. Investig. 75:827-841[Medline]. |
| 4. | Dezube, B. J., A. B. Pardee, B. Chapman, L. A. Beckett, J. A. Korvick, W. J. Novick, J. Chiurco, P. Kasdan, C. M. Ahlers, L. T. Ecto, et al. 1993. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J. Acquired Immune Defic. Syndr. 6:787-794. |
| 5. | Fagan, M. A., Y. Liu, P. Stutz, H. Vyplel, and D. T. Golenbock. 1994. Acyclic analogue of lipid A stimulates TNF-alpha and arachidonate release via a unique LPS-signaling pathway. J. Immunol. 153:5230-5238[Abstract]. |
| 6. | Fei, D. T., H. Paxton, and A. B. Chen. 1993. Difficulties in precise quantitation of CD4+ T lymphocytes for clinical trials: a review. Biologicals 21:221-231[Medline]. |
| 7. | Fletcher, M. A., G. C. Baron, M. R. Ashman, M. A. Fischl, and N. G. Klimas. 1987. Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn. Clin. Immunol. 5:69-81[Medline]. |
| 8. | Fuchs, A. C., E. V. Granowitz, L. Shapiro, E. Vannier, G. Lonnemann, J. B. Angel, J. S. Kennedy, A. R. Rabson, E. Radwanski, M. B. Affrime, D. L. Cutler, P. C. Grint, and C. A. Dinarello. 1996. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J. Clin. Immunol. 16:291-303[Medline]. |
| 9. |
Hampton, R. Y.,
D. T. Golenbock, and C. R. Raetz.
1988.
Lipid A binding sites in membranes of macrophage tumor cells.
J. Biol. Chem.
263:14802-14807 |
| 10. |
Heimark, R. L.,
D. R. Twardzik, and S. M. Schwartz.
1986.
Inhibition of endothelial regeneration by type-beta transforming growth factor from platelets.
Science
233:1078-1080 |
| 11. |
Hirsch, C. S.,
R. Hussain,
Z. Toossi,
G. Dawood,
F. Shahid, and J. J. Ellner.
1996.
Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production.
Proc. Natl. Acad. Sci. USA
93:3193-3198 |
| 12. |
Huizinga, T. W.,
B. A. Dijkmans,
E. A. van der Velde,
T. C. van de Pouw Kraan,
C. L. Verweij, and F. C. Breedveld.
1996.
An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis.
Ann. Rheum. Dis.
55:833-836 |
| 13. | Jacobson, M. A., M. Zegans, P. R. Pavan, J. J. O'Donnell, F. Sattler, N. Rao, S. Owens, and R. Pollard. 1997. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349:1443-1445[Medline]. |
| 14. |
Kinter, A. L.,
G. Poli,
W. Maury,
T. M. Folks, and A. S. Fauci.
1990.
Direct and cytokine-mediated activation of protein kinase C induces human immunodeficiency virus expression in chronically infected promonocytic cells.
J. Virol.
64:4306-4312 |
| 15. | Lederman, M., E. Connick, A. Landay, H. Kessler, D. Kurtizkes, M. St. Clair, L. Fox, M. Heath-Chiozzi, F. Rousseau, and J. Spritzler. 1997. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir): preliminary results of ACTG 315, p. 208. In 4th Conference on Retroviruses and Opportunistic Infection, vol. 4, abstr. LB13. . |
| 16. | Leroux, M., L. Schindler, R. Braun, H. W. Doerr, H. P. Geisen, and H. Kirchner. 1985. A whole-blood lymphoproliferation assay for measuring cellular immunity against herpes viruses. J. Immunol. Methods 79:251-262[Medline]. |
| 17. | Lolli, F., L. B. Chen, V. A. Sundqvist, H. Link, V. Holmberg, and B. Wahren. 1994. HIV antigen-reactive T cells detected by antigen-induced interferon gamma secretion. AIDS Res. Hum. Retroviruses 10:115-120[Medline]. |
| 18. |
Makonkawkeyoon, S.,
R. N. Limson Pobre,
A. L. Moreira,
V. Schauf, and G. Kaplan.
1993.
Thalidomide inhibits the replication of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
90:5974-5978 |
| 19. | Malone, J. L., T. E. Simms, G. C. Gray, K. F. Wagner, J. R. Burge, and D. S. Burke. 1990. Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J. Acquired Immune. Defic. Syndr. 3:144-151. |
| 20. | Perenboom, R. M., P. Beckers, J. W. Van Der Meer, A. C. Van Schijndel, W. J. Oyen, F. H. Corstens, and R. W. Sauerwein. 1996. Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. J. Leukocyte Biol. 60:710-715[Abstract]. |
| 21. | Race, E. M., J. Adelson-Mitty, G. R. Kriegel, T. F. Barlam, K. A. Reimann, N. L. Letvin, and A. Japour. 1998. Focal mycobacterial lymphadenitis following initiation of protease inhibitor therapy in patients with advanced HIV-1 disease. Lancet 351:252-255[Medline]. |
| 22. | Salkowski, C. A., G. Detore, R. McNally, N. van Rooijen, and S. N. Vogel. 1997. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J. Immunol. 158:905-912[Abstract]. |
| 23. | Syrjala, H., E. Herva, J. Ilonen, K. Saukkonen, and A. Salminen. 1984. A whole-blood lymphocyte stimulation test for the diagnosis of human tularemia. J. Infect. Dis. 150:912-915[Medline]. |
| 24. | Vyakarnam, A., P. Matear, A. Meager, G. Kelly, B. Stanley, I. Weller, and P. Beverley. 1991. Altered production of tumour necrosis factors alpha and beta and interferon gamma by HIV-infected individuals. Clin. Exp. Immunol. 84:109-115[Medline]. |
| 25. | Vyakarnam, A., J. McKeating, A. Meager, and P. C. Beverley. 1990. Tumour necrosis factors (alpha, beta) induced by HIV-1 in peripheral blood mononuclear cells potentiate virus replication. AIDS 4:21-27[Medline]. |
| 26. | Wallis, R. S., P. Nsubuga, A. Okwera, C. Whalen, R. D. Mugerwa, D. Oette, J. B. Jackson, J. L. Johnson, and J. J. Ellner. 1996. Pentoxifylline in human immunodeficiency virus-seropositive tuberculosis: a randomized, controlled trial. J. Infect. Dis. 174:727-733[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |